Dual treatment with the glucose-lowering drugs dapagliflozin and exenatide remains effective for patients with diabetes after two years of continual use, according to the results of a late-stage clinical trial.
Diabetes medications Januvia and Byetta significantly increase the risk of pancreatic inflammation, according to Johns Hopkins University School of Medicine researchers.
Johns Hopkins University School of Medicine researchers looked at 1,269 people who took at least one prescription diabetes drug between 2005-2008, comparing them to a control group of 1,269 diabetics who did not take a prescription drug to treat the condition during that period.
